https://www.pharmaceutical-technology.com/data-insights/npx-887-nextpoint-therapeutics-metastatic-renal-cell-carcinoma-likelihood-of-approval/
NPX-887 is under clinical development by NextPoint Therapeutics and currently in Phase I for Metastatic Renal Cell Carcinoma.
renal cell carcinomanpxtherapeuticsmetastatic
https://www.pharmaceutical-technology.com/data-insights/likelihood-of-approval-metastatic-renal-cell-carcinoma/
Metastatic Renal Cell Carcinoma disease is an indication for drug development with over 130 pipeline drugs currently active according to GlobalData.
renal cell carcinomametastaticdrugslikelihoodapproval
https://pubmed.ncbi.nlm.nih.gov/12953756/
Cytoreductive nephrectomy can be an important and effective component of a multidisciplinary treatment approach to metastatic renal cell carcinoma in carefully...
rolenephrectomymanagementmetastatic
https://www.pharmaceutical-technology.com/data-insights/zeluvalimab-amgen-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC).
hepatocellular carcinomaamgenmetastatichcclikelihood
https://pubmed.ncbi.nlm.nih.gov/29988298/
Metastatic lesions of the nasal cavity and paranasal sinuses are rare tumors. Carcinomas originating from intrapelvic organs play an important role in the...
renal cell carcinomanasal septummetastaticcase
https://www.pharmaceutical-technology.com/data-insights/ab-2100-arsenal-biosciences-metastatic-renal-cell-carcinoma-likelihood-of-approval/
AB-2100 is under clinical development by Arsenal Biosciences and currently in Phase II for Metastatic Renal Cell Carcinoma.
renal cell carcinomaabarsenalbiosciencesmetastatic
https://www.pharmaceutical-technology.com/data-insights/mt-303-myeloid-therapeutics-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/
MT-303 is under clinical development by Myeloid Therapeutics and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC).
hepatocellular carcinomamtmyeloidtherapeuticsmetastatic
https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-metastatic-renal-cell-carcinoma-likelihood-of-approval/
AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Renal Cell Carcinoma.
renal cell carcinomaafmmetastaticlikelihood
https://www.pharmaceutical-technology.com/data-insights/imdatifan-nikang-therapeutics-metastatic-renal-cell-carcinoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-350811&utm_campaign=recommended-articles-pi
Imdatifan is under clinical development by NiKang Therapeutics and currently in Phase II for Metastatic Renal Cell Carcinoma.
renal cell carcinomatherapeuticsmetastaticlikelihood
https://www.researchandmarkets.com/reports/5951654/recurrent-or-metastatic-nasopharyngeal
Recurrent or Metastatic Nasopharyngeal Carcinoma Overview 'Recurrent or Metastatic Nasopharyngeal Carcinoma Pipeline Insight, 2025' report outlays...
nasopharyngeal carcinomarecurrentmetastaticpipelineinsight
https://www.pharmaceutical-technology.com/data-insights/vg-161-virogin-biotech-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/
VG-161 is under clinical development by Virogin Biotech and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).
hepatocellular carcinomavgbiotechmetastatichcc